文献速递甲状腺疾病

分化型甲状腺癌患者的无治疗生存期

Treatment-Free Survival in Patients With Differentiated Thyroid Cancer.
PubMed 文献 · J Clin Endocrinol Metab · 2018-01-01

基于SEER-Medicare数据库9273例1998-2012年诊断的分化型甲状腺癌患者,采用生存树和随机生存森林分析,识别出5个无治疗生存期预后组(P<0.001),预测准确率88.7%,5年无治疗生存率分别为96%、91%、85%、72%、52%,10年分别为94%、87%、80%、64%、39%。

要点

  • 5个预后组5年无治疗生存率分别为96%、91%、85%、72%、52%。
  • 10年无治疗生存率分别为94%、87%、80%、64%、39%。
  • 预测无治疗生存期最重要的因素为分期、肿瘤大小和是否接受放射性碘治疗。

核心结论

  • 在基于人群的队列中识别出5个无治疗生存期预后组,理解无治疗生存期对分化型甲状腺癌患者的护理和长期监测有意义。

研究设计与样本

  • 基于人群的研究,纳入SEER-Medicare数据库中1998-2012年诊断的9273例分化型甲状腺癌患者,中位诊断年龄69岁,75%为女性。
  • 采用Cox比例风险回归、生存树和随机生存森林进行多变量分析。

主要发现

  • 生存树分析识别出5个不同的预后组(P < 0.001),预测准确率为88.7%。
  • 5年无治疗生存率分别为96%、91%、85%、72%、52%,10年无治疗生存率分别为94%、87%、80%、64%、39%。
  • 基于生存森林分析,预测无治疗生存期最重要的因素为分期、肿瘤大小和是否接受放射性碘治疗。

关键数值与推荐

  • 治疗复发定义为诊断后≥1年因复发或持续存在的分化型甲状腺癌接受手术、放射性碘或放疗。

临床怎么用

  • 了解无治疗生存期对分化型甲状腺癌患者的护理和长期监测有意义。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Cancer recurrence is a primary concern for patients with differentiated thyroid cancer; however, population-level data on recurrent or persistent disease do not currently exist. The objective of this study was to determine treated recurrent or persistent thyroid cancer by using a population-based registry, identify correlates of poor treatment-free survival, and define prognostic groups for treatment-free survival. METHODS: In this population-based study, we evaluated treatment-free survival in 9273 patients from the Surveillance, Epidemiology, and End Results Program-Medicare with a diagnosis of differentiated thyroid cancer between 1998 and 2012. Treated recurrence was defined by treatment of recurrent or persistent differentiated thyroid cancer with surgery, radioactive iodine, or radiation therapy at ≥1 year after diagnosis. Multivariable analysis was performed with Cox proportional hazards regression, survival trees, and random survival forests. RESULTS: In this cohort the median patient age at time of diagnosis was 69 years, and 75% of the patients were female. Using survival tree analyses, we identified five distinct prognostic groups (P < 0.001), with a prediction accuracy of 88.7%. The 5-year treatment-free survival rates of these prognostic groups were 96%, 91%, 85%, 72%, and 52%, respectively, and the 10-year treatment-free survival rates were 94%, 87%, 80%, 64%, and 39%. Based on survival forest analysis, the most important factors for predicting treatment-free survival were stage, tumor size, and receipt of radioactive iodine. CONCLUSION: In this population-based cohort, five prognostic groups for treatment-free survival were identified. Understanding treatment-free survival has implications for the care and long-term surveillance of patients with differentiated thyroid cancer.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Banerjee M, Reyes-Gastelum D, Haymart MR, et al. Treatment-Free Survival in Patients With Differentiated Thyroid Cancer. J Clin Endocrinol Metab. 2018. PMID: 29788217. doi:10.1210/jc.2018-00511

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。